BMRN241220C90000
- 0.15
- 0.000.00%
Biomarin Pharmaceutical Newsroom
RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
Despite Delivering Investors Losses of 26% Over the Past 1 Year, BioMarin Pharmaceutical (NASDAQ:BMRN) Has Been Growing Its Earnings
Express News | Biomarin Pharmaceutical Inc : RBC Cuts Target Price to $70 From $80
Here's Why BioMarin Pharmaceutical (BMRN) Is a Strong Value Stock
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $122
Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now
Biomarin Pharmaceutical To Present At Jefferies London Healthcare Conference; Webcast At 4:00 AM ET
Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research
Biomarin Pharmaceutical Analyst Ratings
Wolfe Research Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $95
Biomarin Pharmaceutical Insider Sold Shares Worth $350,324, According to a Recent SEC Filing
Biomarin Pharmaceutical To Present At UBS Global Healthcare Conference; Webcast At 2:00 PM ET
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options
Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)
Is BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Recent Price Movement Underpinned By Its Weak Fundamentals?
Peering Into Biomarin Pharmaceutical's Recent Short Interest